Does treatment at sarcoma centers improve prognosis in STS?

Individuals with soft-tissue sarcoma who receive multidisciplinary therapy at sarcoma centers may have improved prognoses, according to a new study.

Researchers analyzed the clinical findings and prognoses of 72 patients before the establishment of a sarcoma center and 155 patients treated at the center.

After the sarcoma center was completed, the mean number of patients went from 36.0 to 51.7 per year, with a greater proportion of patients with stage IV disease (8.3% to 12.9%).

After the establishment of the sarcoma center, there was a slight decrease in the 3-year survival rate of patients for all stages, dropping from 80.0% to 78.3%. However, the 3-year survival rate for patients with stage II and III disease showed a notable increase, rising from 78.6% to 84.7%. Similarly, the 3-year survival rate for patients with stage III retroperitoneal sarcoma also improved significantly, increasing from 70.0% to 86.7%. Despite these improvements, there was no statistically significant difference observed in the survival curves.

Reference
Yonemoto T, Kamoda H, Hagiwara Y, et al. Does Multidisciplinary Therapy at a Sarcoma Center Improve the Prognosis of Patients With Soft Tissue Sarcoma? A Retrospective Case Study at a Single Institute. Anticancer Res. 2023;43(5):2317-2321. doi: 10.21873/anticanres.16396. PMID: 37097691.